THAT WHICH IS CLAIMED IS:

1. Use of a K_{ATP} channel opener in the manufacture of a medicament for treatment to reduce one or more aggressive behaviors in a subject having Prader-Willi syndrome (PWS) or Smith–Magenis syndrome (SMS),

wherein the medicament is to be administered to said subject for at least 10 weeks in an effective amount,

wherein the administration reduces one or more aggressive behaviors in the subject, and

wherein said K_{ATP} channel opener is diazoxide or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the medicament further comprises a second therapeutic product, wherein the second therapeutic product is intended to further reduce the one or more aggressive behaviors in the subject.

3. Use of a K_{ATP} channel opener in the manufacture of a medicament for treatment to reduce hyperghrelinemia in a subject having Prader-Willi syndrome (PWS) or Smith–Magenis syndrome (SMS),

wherein the medicament is to be administered to said subject for at least 10 weeks in an effective amount,

wherein the administration reduces one or more aggressive behaviors in the subject, and

wherein said K_{ATP} channel opener is diazoxide or a pharmaceutically acceptable salt thereof.

4. The use of any one of claims 1 to 3, wherein the K_{ATP} channel opener is a pharmaceutically acceptable salt of diazoxide.

5. The use of claim 4, wherein the pharmaceutically acceptable salt is diazoxide choline.

6. The use of any one of claims 1 to 3, wherein the K_{ATP} channel opener is diazoxide.

7. The use of claim 5, wherein the medicament includes at least one excipient which affects the rate of release of diazoxide choline or a pharmaceutically acceptable salt thereof.

8. The use of any one of claims 1 to 3, wherein the medicament includes at least one excipient that delays release of diazoxide or a pharmaceutically acceptable salt thereof.

9. The use of any one of claims 1 to 3, wherein the medicament further comprises at least one other active ingredient.

10. The use of any one of claims 1 to 3, wherein the medicament further comprises human growth hormone, and the human growth hormone is to be administered to the subject.

11 The use of claim 10, wherein said human growth hormone is to be administered by injection.

12. The use of any one of claims 1 to 3, wherein said diazoxide or a pharmaceutically acceptable salt thereof is to be administered orally.

13. The use of any one of claims 1 to 3, wherein the medicament is to be administered twice per day.

14. The use of any one of claims 1 to 3, wherein the medicament is to be administered once per day.

15. The use of any one of claims 1 to 3, wherein said administering is carried out for one or more years.

16. The use of any one of claims 1 to 3, wherein the circulating concentration of IGF-1 is not increased.

17. The use of any one of claims 1 to 3, wherein the medicament consists essentially of diazoxide or a pharmaceutically acceptable salt thereof.